Heart Failure Clinical Trials in New York, New York

33 studies are recruiting for heart failure in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Alleviant ALLAY-HFrEF Study

   Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Stony Brook Medicine, New York, New York

   Locations

   68 in total

   Run by

   Alleviant Medical, Inc.

   See if you can join NCT06812533 on ClinicalTrials.gov

2. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

   Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

   Stage

   Phase 3

   Ages

   40 and older

   Site

   Research Site, New York, New York

   Locations

   957 in total

   Run by

   AstraZeneca

   See if you can join NCT06677060 on ClinicalTrials.gov

3. The WiSE®-UP Study (The WiSE System Utilization & Performance Study)

   Observe to understand product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System

   Stage

   Not phased

   Ages

   22 and older

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   12 in total

   Run by

   EBR Systems, Inc.

   See if you can join NCT07098858 on ClinicalTrials.gov

4. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

   The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

   Stage

   Not phased

   Ages

   18 to 100

   Site

   NYU Langone Health, New York, New York

   Locations

   47 in total

   Run by

   BrioHealth Solutions, Inc.

   See if you can join NCT06310031 on ClinicalTrials.gov

5. A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

   This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Mount Sinai Hospital-New York-52529, New York, New York

   Locations

   588 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT06935370 on ClinicalTrials.gov

6. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

   This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

   Stage

   Phase 2

   Ages

   0 to 17

   Site

   Columbia University Medical Center-Pediatric Cardiology ( Site 0016), New York, New York

   Locations

   109 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05714085 on ClinicalTrials.gov

7. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

   The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

   Stage

   Phase 3

   Ages

   18 to 85

   Site

   Mount Sinai Hospital, New York, New York

   Locations

   205 in total

   Run by

   Cytokinetics

   See if you can join NCT06736574 on ClinicalTrials.gov

8. Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

   Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec…

   Stage

   Not phased

   Ages

   21 and older

   Site

   Mount Sinai Morningside, New York, New York

   Locations

   50 in total

   Run by

   Procyrion

   See if you can join NCT05677100 on ClinicalTrials.gov

9. NORM-HF Pivotal Study

   This is an international, multi-center, prospective, randomized, open-label blinded endpoint study designed to demonstrate that use of the FIRE1 NORM™ System in the management of New York Heart Association Class II/III HF patients is superior for reducing the combined endpoint of worsening HF event…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Columbia University Irving Medical Center/ New York Presbyterian Hospital, New York, New York

   Locations

   9 in total

   Run by

   Foundry Innovation & Research 1, Limited (FIRE1)

   See if you can join NCT07574593 on ClinicalTrials.gov

10. A Preliminary Study for INFORMED

    Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding their preference to continue or discontinue beta-blockers in older adu…

    Stage

    Phase 4

    Ages

    65 and older

    Site

    Weill Cornell Medicine, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT05585125 on ClinicalTrials.gov

11. Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)

    This study is trying to improve the hospital-to-home transition for people with heart failure who receive home care services. The study will test an intervention called I-TRANSFER-HF, which differs from usual care by combining early home health nurse visits and outpatient medical appointments. The …

    Stage

    Not phased

    Ages

    18 and older

    Site

    VNS Health Partners in Care, New York, New York

    Locations

    2 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06118983 on ClinicalTrials.gov

12. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

    This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Locations

    652 in total

    Run by

    Boehringer Ingelheim

    See if you can join NCT06424288 on ClinicalTrials.gov

13. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    Stage

    Not phased

    Ages

    Any age

    Site

    Research site, New York, New York

    Locations

    333 in total

    Run by

    Medtronic

    See if you can join NCT00271180 on ClinicalTrials.gov

14. Impella Reverse Remodeling in End-Stage Heart Failure

    This observational study is being done to learn more about heart attack recovery in patients supported with the Impella 5.5 left ventricular assist device (LVAD) as part of their standard of care. There are three stages in this study: screening, treatment and post treatment. There will be two phase…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Columbia University, New York, New York

    Run by

    Columbia University

    See if you can join NCT06800716 on ClinicalTrials.gov

15. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    NYU Langone Med Assoc Chelsea, New York, New York

    Locations

    838 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT07567001 on ClinicalTrials.gov

16. Alleviant ALLAY-HF Study

    Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

    Stage

    Not phased

    Ages

    40 and older

    Site

    New York University, New York, New York

    Locations

    93 in total

    Run by

    Alleviant Medical, Inc.

    See if you can join NCT05685303 on ClinicalTrials.gov

17. CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)

    The purpose of this multi-center clinical trial is to study the efficacy and safety of providing nutritional support added to the study-defined standard of care which consists of standardized dietary education and a single dietary counseling session shortly after discharge, versus study-defined sta…

    Stage

    Not phased

    Ages

    60 and older

    Site

    VA NY Harbor Healthcare System, New York, NY, New York, New York

    Locations

    16 in total

    Run by

    VA Office of Research and Development

    See if you can join NCT05996328 on ClinicalTrials.gov

18. MediBeacon® Transdermal GFR System for the Evaluation of Kidney Function in Adults With Heart Failure

    The goal of this clinical trial is to evaluate the accuracy and feasibility of transdermal glomerular filtration rate (tGFR) assessment using relmapirazin (Lumitrace) and the MediBeacon tGFR system compared to plasma clearance measurement of GFR in adults with heart failure. The main question it ai…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Columbia University, New York, New York

    Run by

    MediBeacon

    See if you can join NCT07349797 on ClinicalTrials.gov

19. Improving Self-Care of Caregivers of Adults in Homecare With Heart Failure and Cognitive Impairment

    This RCT design will enroll 256 informal caregivers (spouse/partner or child) of HHC patients with HF/CI and 60 patients with HF and mild to moderate CI (60 dyads). After collecting baseline data, we will block randomize the caregivers 1:1 to the ViCCY intervention or comparator group, stratifying …

    Stage

    Not phased

    Ages

    18 to 101

    Site

    VNS Health, New York, New York

    Run by

    Visiting Nurse Service of New York

    See if you can join NCT07220798 on ClinicalTrials.gov

20. Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

    There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of sup…

    Stage

    Phase 2

    Ages

    0 to 16

    Site

    Cuimc/Nyph, New York, New York

    Locations

    5 in total

    Run by

    Stanford University

    See if you can join NCT06080074 on ClinicalTrials.gov

21. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Weill Cornell Medicine, New York, New York

    Locations

    105 in total

    Run by

    Impulse Dynamics

    See if you can join NCT05064709 on ClinicalTrials.gov

22. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

    This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

    Stage

    Phase 2

    Ages

    40 to 84

    Site

    Icahn Sch of Med-Mt Sinai Hosp, New York, New York

    Locations

    117 in total

    Run by

    Novo Nordisk A/S

    See if you can join NCT06979362 on ClinicalTrials.gov

23. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

    This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mount Sinai West, New York, New York

    Locations

    48 in total

    Run by

    Endotronix, Inc.

    See if you can join NCT05934487 on ClinicalTrials.gov

24. Quantifying New Heart Muscle Cells

    Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease a…

    Stage

    Not phased

    Ages

    0 to 1

    Site

    Weill Cornell Medicine, New York, New York

    Locations

    4 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06587165 on ClinicalTrials.gov

25. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

    The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

    Stage

    Not phased

    Ages

    18 and older

    Site

    New York-Presbyterian/Columbia University Medical Center, New York, New York

    Locations

    68 in total

    Run by

    Abbott Medical Devices

    See if you can join NCT06526195 on ClinicalTrials.gov